Nuvectis Pharma, Inc. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Nuvectis Pharma, Inc. (NVCT) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $1.40 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2023-05-10
- Nuvectis Pharma, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2023-03-31 was $1.40M, a 798.72% increase year-over-year.
- Nuvectis Pharma, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2022-12-31 was $482.00K.
- Nuvectis Pharma, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2022-09-30 was $559.00K, a 311.03% increase year-over-year.
- Nuvectis Pharma, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for the quarter ending 2022-06-30 was $510.00K, a 67.54% decline year-over-year.
- Nuvectis Pharma, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2022 was $1.71M, a 9.78% decline from fiscal 2021.
- Nuvectis Pharma, Inc. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2021 was $1.89M.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 3 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 6 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 9 month | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|---|---|---|
| 2023-03-31 | $1.40M 10-Q · filed 2023-05-10 | $1.88M derived: sum of 2 quarters · filed 2023-05-10 | $2.44M derived: sum of 3 quarters · filed 2023-05-10 | $2.95M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $482.00K derived: 10-K 12 month − 3 quarters · filed 2023-03-08 | $1.04M derived: sum of 2 quarters · filed 2023-03-08 | $1.55M derived: sum of 3 quarters · filed 2023-03-08 | $1.71M 10-K · filed 2023-03-08 |
| 2022-09-30 | $559.00K 10-Q · filed 2022-11-08 | $1.07M derived: sum of 2 quarters · filed 2022-11-08 | $1.23M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2022-06-30 | $510.00K 10-Q · filed 2022-11-08 | $666.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2022-03-31 | $156.00K 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $1.89M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $136.00K 10-Q · filed 2022-11-08 | $1.71M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $1.57M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |